Literature DB >> 19262953

Editorial: CTAD International Research Conference: Clinical Trials in Alzheimer's Disease.

S Gauthier.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19262953

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN： 1279-7707            Impact factor:   4.075


× No keyword cloud information.
  13 in total

1.  The influence of matrix type, diurnal rhythm and sample collection and processing on the measurement of plasma beta-amyloid isoforms using the INNO-BIA plasma Abeta forms multiplex assay.

Authors:  D R Lachno; H Vanderstichele; G De Groote; V Kostanjevecki; G De Meyer; E R Siemers; M B Willey; J S Bourdage; R J Konrad; R A Dean
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075

2.  Critical evaluation of self-rated quality of life in mild cognitive impairment and Alzheimer's disease--further evidence for the impact of anosognosia and global cognitive impairment.

Authors:  M Berwig; H Leicht; H J Gertz
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075

3.  Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment.

Authors:  K Blennow; G De Meyer; O Hansson; L Minthon; A Wallin; H Zetterberg; P Lewczuk; H Vanderstichele; E Vanmechelen; J Kornhuber; J Wiltfang; I Heuser; W Maier; C Luckhaus; E Rüther; M Hüll; H Jahn; H J Gertz; L Frölich; H Hampel; R Pernetzki
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075

4.  New insights into clinical trial for Colostrinin in Alzheimer's disease.

Authors:  P Szaniszlo; P German; G Hajas; D N Saenz; M Kruzel; I Boldogh
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075

5.  Analytic methods for factors, dimensions and endpoints in clinical trials for Alzheimer's disease.

Authors:  R E Tractenberg
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075

6.  Methodological improvements in quantifying cognitive change in clinical trials: an example with single-dose administration of donepezil.

Authors:  R H Pietrzak; P Maruff; P J Snyder
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075

Review 7.  Short review: Acetylcholinesterase-inhibitors in Alzheimer's disease have opposing effects on blood pressure and cerebral perfusion.

Authors:  J A H R Claassen; A H E A van Beek; M G M Olde Rikkert
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075

8.  GAB2 gene does not modify the risk of Alzheimer's disease in Spanish APOE 4 carriers.

Authors:  R Ramirez-Lorca; M Boada; M E Saez; I Hernandez; A Mauleon; M Rosende-Roca; P Martinez-Lage; M Gutierrez; L M Real; J Lopez-Arrieta; J Gayan; C Antunez; A Gonzalez-Perez; L Tarraga; A Ruiz
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075

Review 9.  Development of AFFITOPE vaccines for Alzheimer's disease (AD)--from concept to clinical testing.

Authors:  A Schneeberger; M Mandler; O Otawa; W Zauner; F Mattner; W Schmidt
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075

10.  Cost-effectiveness of post-diagnosis treatment in dementia coordinated by Multidisciplinary Memory Clinics in comparison to treatment coordinated by general practitioners: an example of a pragmatic trial.

Authors:  E J Meeuwsen; P German; R J F Melis; E M Adang; G A Golüke-Willemse; P F Krabbe; B J de Leest; F H J M van Raak; C J M Schölzel-Dorenbos; M C Visser; C A Wolfs; S Vliek; M G M Olde Rikkert
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.